Case Report

Four Japanese Patients with Congenital Nephrogenic Diabetes Insipidus due to the AVPR2 Mutations

Noriko Namatame-Ohta 
Shuntaro Morikawa 
Akie Nakamura 
Kumihiro Matsuo 
Masahide Nakajima 
Kazuhiro Tomizawa 
Yusuke Tanahashi 
and Toshihiro Tajima

1Department of Pediatrics, Hokkaido University Graduate School of Medicine, North 15 West 7, Kita-ku, Sapporo 060-8638, Japan
2Department of Pediatrics, Asahikawa City Hospital, 1-1-65 Kinsei-cho, Asahikawa 070-8610, Japan
3Department of Molecular Endocrinology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan
4Department of Pediatrics, Asahikawa Medical University, 2-1-1-1 Midorigaoka-higashi, Asahikawa 078-8510, Japan
5Department of Pediatrics, Nakashibetsu Town Hospital, West 10 South 9, Nakashibetsu 086-1110, Japan
6Department of Pediatrics, Jichi Children’s Medical Center Tochigi, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan

Correspondence should be addressed to Noriko Namatame-Ohta; noriko.o.n@hhup.hokudai.ac.jp

Received 25 January 2018; Revised 23 March 2018; Accepted 16 April 2018; Published 3 July 2018

Academic Editor: Yusuke Shiozawa

Copyright © 2018 Noriko Namatame-Ohta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Almost 90% of nephrogenic diabetes insipidus (NDI) is caused by mutations in the arginine vasopressin receptor 2 gene (AVPR2) on the X chromosome. Herein, we reported clinical and biochemical parameters in four cases of three unrelated Japanese families and analyzed the status of AVPR2. Two of the four patients had poor weight gain. However, in the male and female sibling cases, neither had poor weight gain while toddlers, but in the male sibling, episodes of recurrent fever, polyuria, and polydipsia led to the diagnosis of NDI at 4 years of age. Analysis of AVPR2 identified two nonsense mutations (c.299_300insA; p.K100KfsX91 and c.296G>A; p.W99X) and one missense mutation (c.316C>T; p.R106C). These mutations were previously reported. The patient with c.316C>T; p.R106C had milder symptoms consistent with previous reports. Of the familial cases, the sister was diagnosed as having NDI, but a skewed X-inactivation pattern in her peripheral blood lymphocytes was not identified. In conclusion, our study expands the spectrum of phenotypes and characterized mutations in AVPR2 in NDI.

1. Introduction

Nephrogenic diabetes insipidus (NDI) is a rare disease that is characterized by resistance of the distal renal tubule and collecting ducts to arginine vasopressin [1, 2]. Vast majority of NDI is caused by mutations in the arginine vasopressin receptor 2 gene (AVPR2) on the X chromosome [3]. At present, more than 250 mutations have been reported [2]. Mutations in AVPR2 were classified into three types. Type-I mutants reach the cell surface but cannot bind its ligand, type-II mutant receptors have impaired intracellular transport and cannot reach the cell surface, and type-III mutants are inappropriately transcribed [4, 5].

Common symptoms in male patients are polyuria, polydipsia, fever of unknown etiology, convulsions, and vomiting, which usually develop soon after birth [6]. On the other hand, female cases have only mild symptoms [7]. Furthermore, some mutations in the AVPR2 are related to partial NDI [8, 9].

In this study, we assessed the clinical and biochemical parameters and AVPR2 status in four NDI cases of three unrelated Japanese families.
### Table 1: Clinical characteristics of 4 patients with congenital nephrogenic diabetes insipidus and AVPR2 mutations.

|                  | Case 1                                      | Case 2                                      | Case 3                                      | Case 4                                      |
|------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| Sex              | Male                                        | Male                                        | Male                                        | Female                                      |
| AVPR2 mutation   | c.299_300insA; p.K100KfsX91                  | c.316C>T; p.R106C                            | c.296G>A; p.W99X                            | c.296G>A; p.W99X                            |
| Age              | 3 mo                                        | 19 mo                                       | 4 y                                         | 4 y                                         |
| Symptoms*        | Polydipsia, polyuria, poor body weight gain, vomiting, fever | Polydipsia, polyuria, poor body weight gain, low-grade fever | Polydipsia, polyuria | Polydipsia, polyuria |
| Laboratory data* | Serum Na (mEq/L) 162                        | 139                                        | 138                                         | 141                                         |
|                  | ADH** (pmol/L) 29.4                         | 12.7                                       | 53.1                                        | 6.2                                         |
|                  | Plasma osmolality (mOsm/L) 325              | 280                                        | 278                                         | 283                                         |
|                  | Urine osmolality (mOsm/L) 183               | 74.0                                       | None                                        | 175                                         |
|                  | Urologic complications                      | Calcification (right kidney), mild hydronephrosis (left kidney) | None                                        | None                                        |
|                  | Current treatment                           | HCTZ, SP, potassium supplement, IDM         | HCTZ, potassium supplement, IDM             | HCTZ, potassium supplement, IDM             |

*Time of diagnosis; **normal range: 0.9–4.6 pmol/L. ADH, plasma antidiuretic hormone; HCTZ, hydrochlorothiazide; SP, spironolactone; TCM, trichlormethiazide; IDM, indomethacin.

### 2. Subjects and Methods

#### 2.1. Subjects. Clinical symptoms, age at diagnosis, biochemical data, and current treatment are summarized in Table 1. All four patients had polyuria and polydipsia, and results of biochemical evaluations showed high plasma antidiuretic hormone (ADH) levels. Based on these findings, NDI was suspected. The Institutional Review Board Committee of Hokkaido University approved this study (approval number 13-061). The patients’ parents provided written informed consent for their children’s participation in this study.

#### 2.1.1. Case 1. A 3-month-old Japanese boy was admitted because of poor body weight gain, vomiting, and fever that had persisted for one week. He was born as a full-term infant with no complications during pregnancy.

At the time of admission, he had polyuria with a urine volume of 700–800 mL/d. Results of laboratory examinations are shown in Table 1. Findings of brain magnetic resonance imaging (MRI) were normal. Based on the polyuria and the high serum ADH level, the infant was diagnosed as having NDI, and hydrochlorothiazide was initiated. Spironolactone and potassium supplementation was added when he was 2 years old and 4 years old, respectively, and indomethacin and a protein-restricted diet were initiated when he was 6 years old. He is currently 13 years old. His height is 150 cm (−0.8 SD), and his weight is 37 kg (−0.6 SD). His urine volume is approximately 7 L/day. He has mild hydronephrosis in the right kidney. His mother is asymptomatic. The family tree of Case 1 is shown in Figure 1(a).

#### 2.1.2. Case 2. In Case 2, poor weight gain was pointed out at the age of 4 months in this male Japanese infant. Polydipsia and polyuria were noted when he was 17 months of age. At that time, his water intake volume was approximately 3 L/d. Previously, he had experienced recurrent mild to moderate fevers of unknown etiology.

The laboratory examinations results are shown in Table 1. The water deprivation test showed elevated serum Na⁺, plasma osmolality, and urine osmolality (Table 2). However, the subcutaneous injection of vasopressin did not greatly increase urine osmolality. Six and a half hours after the test started, his body weight was reduced by 4.1%. Finally, his plasma ADH elevated to 110.1 pmol/L. Brain MRI findings were normal. Based on these findings, a diagnosis of partial NDI was confirmed when he was 19 months of age. Trichlormethiazide was initiated in combination with spironolactone and sodium restriction. This treatment has successfully decreased the patient’s urine volume and water intake, and his body weight has caught up to near normal for his age. Now, he is 3 years old, and his height is 90.8 cm (−0.6 SD) and weight is 12.9 kg (−0.4 SD).

His mother had also complained of mild polydipsia (2,000 mL/day) and polyuria from childhood, and her plasma ADH level was mildly elevated (5.90 pmol/L), but further examination has not been done. The pedigree of this family is shown in Figure 1(b).

#### 2.1.3. Cases 3 and 4. Case 3 is now a 14-year-old Japanese boy. Polydipsia and polyuria were noticed at 4 years of age. He had enuresis every day from infancy. Since he had an elevated plasma ADH level (53.1 pmol/L), he was diagnosed as having NDI. The laboratory data at the time of diagnosis are shown in Table 1. He is being treated with hydrochlorothiazide, potassium supplementation, and indomethacin. Currently, his water intake is approximately 3 L/d. Case 4 is the younger sister of Case 3 and she is now 12 years old. Polydipsia and polyuria were noted when she was 4 years old after the diagnosis of NDI in Case 3. Her plasma ADH level (6.2 pmol/L) was also elevated. She was diagnosed as having NDI, and treatment with hydrochlorothiazide, potassium supplementation, and indomethacin was initiated. Their mother also complained polydipsia and polyuria since her childhood. However, her latest daily urine volume
(2,000 mL/day) did not meet the diagnostic criteria for NDI. The family tree is shown in Figure 1(c).

2.2. Sequence Analysis of AVPR2 and Study of X Chromosome Inactivation. Genomic DNA was extracted from peripheral blood leukocytes of the cases and female carriers. The AVPR2 exon was amplified by polymerase chain reaction (PCR) using the primers as reported previously [10], and PCR products were purified and sequenced directly using an Applied Biosystems 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). The X-inactivation patterns of female carriers were investigated by studying the polymorphic trinucleotide (CAG) repeats in the first exon of the human androgen receptor gene as reported previously [11].

### 3. Results

Hemizygous mutations of AVPR2 were identified in all three male patients (Figure 2). In Case 1, one base insertion caused a frame shift, generating a premature stop codon at codon 191 in exon 2 (c.299_300insA; p.K100KfsX91, designated as p.K100KfsX91). His mother was heterozygous for this mutation. Case 2 had a c.316C>T; p.R106C (designated as p.R106C) in exon 2, which was previously reported [10, 12–17]. His mother was heterozygous for this mutation. Cases 3 and 4 had a nucleotide change of G to A at position 296, resulting in the nonsense substitution (c.296G>A; p.W99X, designated as p.W99X). Their mother and Case 4 were heterozygous for the mutation. These mutations were previously reported.

The values of relative X-inactivation for the normal allele in Case 4 was 67.0%, and the values of mothers of all four patients were 65.0% (Case 1 mother), 62.0% (Case 2 mother), and 58.0% (Case 3 and 4 mother), respectively (Figure 3). Skewed X-inactivation is defined as inactivation of 75–80% of cells in the same allele [18]. Therefore, they had random X-inactivation.

| Test time (hour) | Body weight (g) | Body weight loss (%) | Urine osmolality (mOsm/L) | Serum osmolality (mOsm/L) | Serum Na⁺ (mEq/L) | ADH (pmol/L) |
|-----------------|-----------------|----------------------|--------------------------|--------------------------|------------------|-------------|
| 0               | 9.055           |                      | 68                       | 286                      | 140              | 64.7        |
| 1               | 8.980           | 0.8                  | 291                      |                          |                  |             |
| 2               | 8.905           | 1.6                  | 261                      |                          |                  |             |
| 3               | 8.855           | 2.2                  | 252                      |                          |                  |             |
| 4               | 8.795           | 2.8                  | 252                      |                          |                  |             |
| 5*              | 8.745           | 3.4                  | 314                      | 212                      | 146              | 91.8        |
| 6               | 8.675           | 4.1                  | 378                      | 295                      | 146              | 110.1       |

*Vasopressin was subcutaneously injected. ADH, plasma antidiuretic hormone.
Currently, over 250 mutations in the AVPR2 have been described as the cause of NDI [2]. In our study, three previously reported mutations (p.K100KfsX91, p.W99X, and p.R106C) were identified [12, 17]. The p.K100KfsX91 and p.W99X produced a premature stop codon, resulting in a truncated protein. Regarding p.R106C, that mutation was identified in 7.7% (5/65) of Japanese NDI patients [17] and also was identified in other Asian and ethnic populations [2, 12, 15, 16]. The p.R106C mutation occurs at CpG nucleotides, which are mutation hot spots for genetic diseases.

Although most cases of NDI are diagnosed within the first year of life, some are diagnosed later because of milder symptoms. Especially, several missense mutations have been related to mild phenotypes of NDI [14, 17, 19]. Among our cases, Case 2 with p.R106C had poor weight gain from 4 months of age. Although he did not develop severe dehydration, he had frequent episodes of mild to moderate fever until the diagnosis was made. Pediatricians should keep in mind the possibility of mild NDI during the differential diagnosis of fever with unknown etiology.

**Figure 2:** Results of sequencing of AVPR2 mutations. Sequence chromatograms of AVPR2 in patients and their mothers. Arrows indicate mutation sites.

**Figure 3:** Analysis of X-chromosome inactivation. Arrows indicate the peak fluorescence intensity of the androgen CAG repeat on each X chromosome. Samples were treated with or without HpaII, and fluorescence intensities between treated and untreated samples were compared. The calculated X-inactivation percentage is shown at the bottom of each column.

### 4. Discussion

Currently, over 250 mutations in the AVPR2 have been described as the cause of NDI [2]. In our study, three previously reported mutations (p.K100KfsX91, p.W99X, and p.R106C) were identified [12, 17]. The mutations p.K100KfsX91 and p.W99X produced a premature stop codon, resulting in a truncated protein. Regarding p.R106C, that mutation was identified in 7.7% (5/65) of Japanese NDI patients [17] and also was identified in other Asian and ethnic populations [2, 12, 15, 16]. The p.R106C mutation occurs at CpG nucleotides, which are mutation hot spots for genetic diseases.
References

[1] D. Bockenhauer and D. G. Bichet, “Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus,” Nature Reviews Nephrology, vol. 11, no. 10, pp. 576–588, 2015.

[2] D. G. Bichet and D. Bockenhauer, “Genetic forms of nephrogenic diabetes insipidus (NDI): vasopressin receptor defect (X-linked) and aquaporin defect (autosomal recessive and dominant),” Best Practice & Research Clinical Endocrinology & Metabolism, vol. 30, no. 2, pp. 263–276, 2016.

[3] M. Birnbaumer, A. Seibold, S. Gilbert et al., “Molecular cloning of the receptor for human antidiuretic hormone,” Nature, vol. 357, no. 6376, pp. 333–335, 1992.

[4] T. M. Fujisawa and D. G. Bichet, “Molecular biology of hereditary diabetes insipidus,” Journal of the American Society of Nephrology, vol. 16, no. 10, pp. 2836–2846, 2005.

[5] J. H. Robben, N. V. Knoers, and P. M. Deen, “Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model,” American Journal of Physiology-Renal Physiology, vol. 289, no. 2, pp. F265–F272, 2005.

[6] A. F. van Lieburg, N. V. Knoers, and L. A. Monnens, “Clinical presentation and follow-up of 30 patients with congenital nephrogenic diabetes insipidus,” Journal of the American Society of Nephrology, vol. 10, no. 9, pp. 1958–1964, 1999.

[7] V. Neocleous, N. Skordis, C. Shammas, E. Efstratiou, N. P. Mastroiannopoulos, and L. A. Phylactou, “Identification and characterization of a novel X-linked AVPR2 mutation causing partial nephrogenic diabetes insipidus: a case report and review of the literature,” Metabolism, vol. 61, no. 7, pp. 922–930, 2012.

[8] D. Bockenhauer, E. Carpentier, D. Rochdi et al., “Vasopressin type 2 receptor V88M mutation: molecular basis of partial and complete nephrogenic diabetes insipidus,” Nephrol. Physiol., vol. 114, no. 1, pp. p1–p10, 2010.

[9] K. Takahashi, N. Makita, K. Manaka et al., “V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists,” Journal of Biological Chemistry, vol. 287, no. 3, pp. 2099–2106, 2012.

[10] A. Garcia Castano, G. Perez de Nanclares, L. Madariaga et al., “Novel mutations associated with nephrogenic diabetes insipidus. A clinical-genetic study,” European Journal of Pediatrics, vol. 174, no. 10, pp. 1373–1385, 2015.

[11] R. C. Allen, H. Y. Zoghbi, A. B. Moseley, H. M. Rosenblatt, and J. W. Belmont, “Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation,” American Journal of Human Genetics, vol. 51, no. 6, pp. 1229–1239, 1992.

[12] D. G. Bichet, M. Birnbaumer, M. Lonergan et al., “Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes insipidus,” American Journal of Human Genetics, vol. 55, no. 2, pp. 278–286, 1994.

[13] E. Albertazzi, D. Zanchetta, P. Barbier et al., “Nephrogenic diabetes insipidus: functional analysis of new AVPR2 mutations identified in Italian families,” Journal of the American Society of Nephrology, vol. 11, no. 6, pp. 1033–1043, 2000.

[14] K. Pasel, A. Schulz, K. Timmermann et al., “Functional characterization of the molecular defects causing nephrogenic diabetes insipidus in eight families,” Journal of Clinical Endocrinology & Metabolism, vol. 85, no. 4, pp. 1703–1710, 2000.

[15] C. H. Chen, W. Y. Chen, H. L. Liu et al., “Identification of mutations in the arginine vasopressin receptor 2 gene causing nephrogenic diabetes insipidus in Chinese patients,” Journal of Human Genetics, vol. 47, no. 2, pp. 66–73, 2002.

[16] W. L. Boson, T. Della Manna, D. Damiani et al., “Novel vasopressin type 2 (AVPR2) gene mutations in Brazilian nephrogenic diabetes insipidus patients,” Genetic Testing, vol. 10, no. 3, pp. 157–162, 2006.

[17] M. Fujimoto, S. Okada, Y. Kawashima et al., “Clinical overview of nephrogenic diabetes insipidus based on a nationwide survey in Japan,” Yonago Acta Medica, vol. 57, no. 2, pp. 85–91, 2014.

[18] J. Mink, W. P. Robinson, and C. J. Brown, “A skewed view of X chromosome inactivation,” Journal of Clinical Investigation, vol. 118, no. 1, pp. 20–23, 2008.

[19] E. Spanakis, E. Milord, and C. Gragnoli, “AVPR2 variants and mutations in nephrogenic diabetes insipidus: review and missense mutation significance,” Journal of Cellular Physiology, vol. 217, no. 3, pp. 605–617, 2008.
[20] S. Sasaki, M. Chiga, E. Kikuchi, T. Rai, and S. Uchida, "Hereditary nephrogenic diabetes insipidus in Japanese patients: analysis of 78 families and report of 22 new mutations in AVPR2 and AQP2," Clinical and Experimental Nephrology, vol. 17, no. 3, pp. 338–344, 2013.

[21] A. Sharp, D. Robinson, and P. Jacobs, "Age- and tissue-specific variation of X chromosome inactivation ratios in normal women," Human Genetics, vol. 107, no. 4, pp. 343–349, 2000.

[22] M. Satoh, S. Ogikubo, and A. Yoshizawa-Ogasawara, "Correlation between clinical phenotypes and X-inactivation patterns in six female carriers with heterozygote vasopressin type 2 receptor gene mutations," Endocrine Journal, vol. 55, no. 2, pp. 277–284, 2008.